Nomura Holdings’s Aurinia Pharmaceuticals AUPH Stock Holding History

Nomura Holdings’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.6M	Buy	978,602 +9,692	+1%	+$155K	0.02%	405
2026 Q1	$14.4M	Sell	968,910 -187,223	-16%	-$2.74M	0.04%	335
2025 Q4	$18.4M	Buy	1,156,133 +839,939	+266%	+$11.9M	0.02%	339
2025 Q3	$3.49M	Buy	316,194 +295,444	+1,424%	+$3.23M	0.01%	916
2025 Q2	$176K	Buy	+20,750	New	+$166K	﹤0.01%	1313
2023 Q4	–	Sell	-99,843	Closed	-$776K	–	1775
2023 Q3	$776K	Buy	99,843 +79,453	+390%	+$777K	﹤0.01%	1033
2023 Q2	$197K	Sell	20,390 -20,000	-50%	-$208K	﹤0.01%	1168
2023 Q1	$443K	Hold	40,390	–	–	﹤0.01%	1149
2022 Q4	$174K	Hold	40,390	–	–	﹤0.01%	1122
2022 Q3	$304K	Hold	40,390	–	–	﹤0.01%	1184
2022 Q2	$460K	Hold	40,390	–	–	﹤0.01%	1138
2022 Q1	$509K	Hold	40,390	–	–	﹤0.01%	1294
2021 Q4	$924K	Buy	+40,390	New	+$957K	﹤0.01%	1240

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's AUPH Position: Q2 2026 in Review

Nomura Holdings increased its Aurinia Pharmaceuticals (AUPH) stake by 1% in Q2 2026, buying an estimated $155K and bringing the position to 978,602 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #405.

Nomura Holdings first reported a position in AUPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $18.4M in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Nomura Holdings held 978,602 shares of Aurinia Pharmaceuticals worth $16.6M as of Q2 2026.
Nomura Holdings bought 9,692 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $155K.
Aurinia Pharmaceuticals made up 0.02% of Nomura Holdings's portfolio in Q2 2026, its #405 holding.
Nomura Holdings first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
Nomura Holdings's Aurinia Pharmaceuticals position peaked at $18.4M in Q4 2025.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.